Almirall says ADlong extension trial shows lebrikizumab sustains EASI-75 response in 92.9% at week 108

• Almirall disclosed late-breaking long-term data from the Phase 3b ADlong extension study of lebrikizumab in atopic dermatitis.
• Results were presented at EADV 2026, tracking patients for up to five years of continued treatment exposure.
• The update showed sustained disease control over time, supporting durable symptom relief in moderate-to-severe patients.
• Safety remained consistent with earlier trials, with no new long-term safety signals flagged in the follow-up.
• The readout strengthens the product’s long-term evidence base in Europe, where it is marketed as Ebglyss.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Almirall SA published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.